← Back
$ENTA All transactions

ENANTA PHARMACEUTICALS INC

F

$ Value

$49K

Shares

3,413

Price

$14

Filed

Feb 13

Insider

Name

Or Yat Sun

Title

Chief Scientific Officer

CIK

0001571212

Roles

Officer

Transaction Details

Transaction Date

2026-02-12

Code

F

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

374,854

Footnotes

Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026. | Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026. | Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

Filing Info

Accession No.

0002064832-26-000008

Form Type

4

Issuer CIK

0001177648

Or Yat Sun's History

Date Ticker Type Value
2026-02-12 ENTA A $0
2026-02-12 ENTA A $0
2026-02-12 ENTA F $49K
2025-12-05 ENTA $34K
2025-12-01 ENTA F $11K
2025-11-25 ENTA A $0

Other Insiders at ENTA (90d)

Insider Bought Sold Last
CARTER BRUCE L A 2026-03-11
FOLETTA MARK G 2026-03-11
Russell Lesley 2026-03-11
Peterson Kristine 2026-03-11
Luly Jay R.
President and CEO
2026-02-12
Or Yat Sun
Chief Scientific Officer
2026-02-12
Vance Terry 2026-03-11
Hata Yujiro S 2026-03-11
Kowalsky Matthew Paul
Chief Legal Officer
2026-02-12
Kieffer Tara Lynn
Chief Product Strategy Officer
2026-02-12
Luu Brendan
Chief Business Officer
2026-02-12
Rottinghaus Scott T.
Chief Medical Officer
2026-02-12